CJC-1295+DAC – Peptide Overview
As previously mentioned, CJC-1295+ DAC was developed by ConjuChem Biotechnologies, where the company modified Growth Hormone Releasing Hormone (GHRH), to preserve its benefits while steering clear of the negative effects.
One such modification consists of only the first 29 amino acids of GHRH and is called CJC-1295. Additional effort was then made to prolong its half-life, eliminate some harmful effects, improve its action duration, and generally get a more soluble GH secretagogue, that would be easier to produce in larger quantities, while preserving its effectiveness.
Some might say that CJC-1295 is similar to other GH analogues (such as Sermorelin), but this is not entirely true. Though they are similar, the two peptides differ in structure and mechanism of action.
DAC (drug affinity complex) was added to the original peptide compound to protect it while it circulates the bloodstream. This led to the increased half-life of the peptide and prolonged action.
CJC-1295+DAC – Research, Studies and Potential Effects
Growth Hormone
Numerous lab studies in mice showed CJC-1295 as an effective way of promoting the release of GH. What researchers saw from the studies was the potency of a single dose to increase GH levels in mice by 2 and up to 10 times! What’s even more surprising is that the peak of this GH secretion in mice was reached approximately 2 hours after the administration, and lasted a full 6 days.
Why researchers find CJC-1295 so interesting and worth testing is that its application preserved the normal physiologic GH release. What this means is they were able to see circadian peaks and valleys present in normal GH release cycles. Preserving this rhythm while simultaneously increasing the amount of the hormone in the bloodstream is what’s ensuring minimal side effects and irregularities.
CJC-1295+ DAC studies were able to show its ability to preserve psychological effects GH has on protein synthesis, myocardial function, bone density, blood sugar, lipid metabolism etc, in mice.
Growth
Since CJC-1295 helps maintain normal circadian rhythm and promotes normal GH release, numerous studies in mice showed its potential in normalizing growth issues in mammalian species.
The only limiting factor to its therapeutic application is its short half-life, which is why scientists are experimenting with adding DAC to improve it.
(In)Fertility
Way back in the 90’s, scientists made the connection between ovarian cycle stimulation and ovulation and IGF-1 hormones (as well as the release of GH). Furthermore, an animal study in superovulation proved that the levels of IGF-1 and GH rose significantly during an ovulation.
This leaves an open question as to if administration of CJC-1295 in infertile animal test subjects has the potential to reverse their infertility. Some additional speculations have been made regarding male infertility and CJC’s potential to regulate sperm production. Sadly, by the time of this writing, no such studies have been done, but we’ll be looking forward to seeing them in the future.
CJC-1295+ DAC – Final Conclusion
Numerous animal studies showed a promising future for this peptide as it not only promotes GH secretion, but does so by maintaining a regular circadian rhythm and normal physiological response.
CJC-1295 also presented itself with only moderate side effects and showed, like many other peptides, modest oral and superb subcutaneous bioavailability in mice testing.
References:
Ionescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog,” J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. 2006.
Jetté, Lucie & Leger, Roger & Thibaudeau, Karen & Benquet, Corinne & Robitaille, Martin & Pellerin, Isabelle & Paradis, Véronique & Wyk, Pieter & Pham, Khan & Bridon, Dominique. (2005). hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog.
Alba et al., “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse,” Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294, Dec. 2006.
Volpe, G. Coukos, A. Barreca, G. Giordano, P. G. Artini, and A. R. Genazzani, “Clinical use of growth hormone-releasing factor for induction of superovulation,” Hum. Reprod., vol. 6, no. 9, pp. 1228–1232, Oct. 1991.
